Finkemeier, Christopher G.
Holy, Chantal E.
Ruppenkamp, Jill W.
Vanderkarr, Mollie
Sparks, C.
Funding for this research was provided by:
Johnson and Johnson
Article History
Received: 10 May 2022
Accepted: 23 August 2022
First Online: 1 September 2022
Declarations
:
: All data in the PREMIER database being de-identified, the use of these data for this study is exempt from Institutional Review Board oversight as dictated by Title 45 Code of Federal Regulations, Part 46 of the United States, specifically 45 CFR 46.101(b)(4). All methods were carried out in accordance with relevant guidelines and regulations. Experimental protocols were drafted and approved by all co-authors and the MedTech Epidemiology research team within the Johnson & Johnson, prior to the conduct of the study.
: Not applicable – no identifiable patient-level data is included in this publication.
: CEH and JWR are employees of Johnson & Johnson (JnJ) and own stock in the company. MV is an employee of DePuy Synthes, a JnJ company. CS was an employee of DePuy Synthes at the time of the study conduct. CGF is a consultant for DePuy Synthes.